The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dysmenorrhea


Psychiatry related information on Dysmenorrhea

  • Also, adolescents who reported more severe dysmenorrhea symptoms following three months of naproxen therapy had significantly lower self-concepts than adolescents who reported less symptoms following treatment [6].

High impact information on Dysmenorrhea


Chemical compound and disease context of Dysmenorrhea

  • Oral contraceptives decreased menstrual flow, reduced prostaglandin release and also alleviated dysmenorrhea [11].
  • Prostaglandins in primary dysmenorrhea. Comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives [11].
  • In an effort to evaluate the discordant role of objective uterine activity known to be associated with primary dysmenorrhea and the subjective sensation of discomfort, data from 18 patients undergoing meclofenamate therapy for primary dysmenorrhea were evaluated [12].
  • Valdecoxib is effective in single doses of up to 40 mg for the alleviation of acute menstrual pain and has a rapid onset of action (within 30 min) and a long duration of analgesia (up to 24 h) [13].
  • There was little evidence for associations between DDE or PCBs and bleeding duration, heavy bleeding, or dysmenorrhea [14].

Biological context of Dysmenorrhea


Anatomical context of Dysmenorrhea


Gene context of Dysmenorrhea


Analytical, diagnostic and therapeutic context of Dysmenorrhea


  1. Flurbiprofen for the treatment of primary dysmenorrhea. Shapiro, S.S. Am. J. Med. (1986) [Pubmed]
  2. Evidence for a reduced histamine degradation capacity in a subgroup of patients with atopic eczema. Maintz, L., Benfadal, S., Allam, J.P., Hagemann, T., Fimmers, R., Novak, N. J. Allergy Clin. Immunol. (2006) [Pubmed]
  3. Selective effect of diclofenac in the treatment of osteoarthritis versus dysmenorrhea. Miller, L.G., Bowman, R.C. Journal of clinical pharmacology. (1990) [Pubmed]
  4. Systematic review of mifepristone for the treatment of uterine leiomyomata. Steinauer, J., Pritts, E.A., Jackson, R., Jacoby, A.F. Obstetrics and gynecology. (2004) [Pubmed]
  5. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Ling, F.W. Obstetrics and gynecology. (1999) [Pubmed]
  6. Factors influencing adolescents' responses to regimens of naproxen for dysmenorrhea. DuRant, R.H., Jay, M.S., Shoffitt, T., Linder, C.W., Taylor, W. Am. J. Dis. Child. (1985) [Pubmed]
  7. Zomepirac sodium in the treatment of primary dysmenorrhea syndrome. Budoff, P.W. N. Engl. J. Med. (1982) [Pubmed]
  8. Mefenamic acid for dysmenorrhea. Dorman, J.M. JAMA (1980) [Pubmed]
  9. Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Dawood, M.Y. Am. J. Med. (1988) [Pubmed]
  10. A double-blind, placebo-controlled study comparing three single-dose regimens of piroxicam with ibuprofen in patients with primary dysmenorrhea. Pasquale, S.A., Rathauser, R., Dolese, H.M. Am. J. Med. (1988) [Pubmed]
  11. Prostaglandins in primary dysmenorrhea. Comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. Chan, W.Y., Dawood, M.Y., Fuchs, F. Am. J. Med. (1981) [Pubmed]
  12. Objective changes in intrauterine pressure during placebo treatment of dysmenorrhea. Smith, R.P. Pain (1987) [Pubmed]
  13. Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Alsalameh, S., Burian, M., Mahr, G., Woodcock, B.G., Geisslinger, G. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  14. Polychlorinated biphenyls and menstrual cycle characteristics. Cooper, G.S., Klebanoff, M.A., Promislow, J., Brock, J.W., Longnecker, M.P. Epidemiology (Cambridge, Mass.) (2005) [Pubmed]
  15. Ketoprofen, ibuprofen, and placebo in the treatment of primary dysmenorrhea: a double-blind crossover comparison. Mehlisch, D.R. Journal of clinical pharmacology. (1988) [Pubmed]
  16. Plasma concentrations of vasopressin and a prostaglandin F2 alpha metabolite in women with primary dysmenorrhoea before and during treatment with a combined oral contraceptive. Hauksson, A., Akerlund, M., Forsling, M.L., Kindahl, H. J. Endocrinol. (1987) [Pubmed]
  17. Rofecoxib: clinical pharmacology and clinical experience. Weaver, A.L. Clinical therapeutics. (2001) [Pubmed]
  18. Vasopressin and prostaglandins in premenstrual pain and primary dysmenorrhea. Strömberg, P., Akerlund, M., Forsling, M.L., Granström, E., Kindahl, H. Acta obstetricia et gynecologica Scandinavica. (1984) [Pubmed]
  19. Effects of suprofen and other prostaglandin synthetase inhibitors in a new animal model for myometrial hyperactivity. Hahn, D.W., Carraher, R., McGuire, J.L. Prostaglandins (1982) [Pubmed]
  20. The effect of ibuprofen on the intrauterine pressure and menstrual pain of dysmenorrheic patients. Pulkkinen, M.O., Csapo, A.I. Prostaglandins (1978) [Pubmed]
  21. Screening of plants used by Southern African traditional healers in the treatment of dysmenorrhoea for prostaglandin-synthesis inhibitors and uterine relaxing activity. Lindsey, K., Jäger, A.K., Raidoo, D.M., van Staden, J. Journal of ethnopharmacology. (1999) [Pubmed]
  22. Glutathione S-transferase M1 and T1 genotypes and endometriosis risk: a case-controlled study. Lin, J., Zhang, X., Qian, Y., Ye, Y., Shi, Y., Xu, K., Xu, J. Chin. Med. J. (2003) [Pubmed]
  23. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea. Harel, Z. Journal of pediatric and adolescent gynecology. (2004) [Pubmed]
  24. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Daniels, S.E., Talwalker, S., Torri, S., Snabes, M.C., Recker, D.P., Verburg, K.M. Obstetrics and gynecology. (2002) [Pubmed]
  25. Dysmenorrhea after bilateral tubal ligation: a case of retrograde menstruation. Morrissey, K., Idriss, N., Nieman, L., Winkel, C., Stratton, P. Obstetrics and gynecology. (2002) [Pubmed]
  26. Mefenamic acid for dysmenorrhea in patients with intrauterine devices. Smith, R.P., Powell, J.R. JAMA (1980) [Pubmed]
  27. Transcutaneous electrical nerve stimulation (TENS) for the treatment of primary dysmenorrhea: a randomized crossover comparison with placebo TENS and ibuprofen. Dawood, M.Y., Ramos, J. Obstetrics and gynecology. (1990) [Pubmed]
  28. Menstrual changes after tubal sterilization. DeStefano, F., Huezo, C.M., Peterson, H.B., Rubin, G.L., Layde, P.M., Ory, H.W. Obstetrics and gynecology. (1983) [Pubmed]
WikiGenes - Universities